Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. (SYRS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
syrs · stock forecast · 9 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Hold
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$30.00
Consensus
$16.67
+8334900.0% upside
Low
$5.00
Median: $15 · Last Close: $0.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.00 | ↑ 0.00% |
1-day model range: $0–$0. Peak: $0 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SYRS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-13 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-11-13 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2024-11-13 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2024-11-13 | Brookline Capital | Downgrade ↓ | Buy→Hold |
| 2024-11-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-13 | Piper Sandler | Maintains | Overweight→Overweight |
| 2024-08-13 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2024-08-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Syros Pharmaceuticals, Inc. (SYRS) stock. Of the recent 33 rating actions, 2 were upgrades and 6 were downgrades. 9 analysts currently cover SYRS.
Analyst Recommendation Trends
SYRS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$5M
↑ 200.0% YoY
Revenue Next Year
$2M
↓ 66.7% YoY
EPS This Year
$-0.95
EPS Next Year
$-0.60
↓ 36.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast SYRS EPS of $-0.95 for the current fiscal year, based on estimates from 2 analysts. The SYRS revenue forecast is $5M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SYRS stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SYRS price target is $16.67 (+8334900.0% upside), with an analyst consensus of Hold.
The SYRS short-term stock prediction for tomorrow is $0.00 (+0.00%).
Syros Pharmaceuticals, Inc. trades on OTC under the ticker SYRS. The SYRS stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 44% of covering analysts.
Frequently asked questions
SYRS forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month SYRS price target is $16.67, with a high forecast of $30.00 and a low of $5.00. The median price target is shown in the chart above when available. This implies +8334900.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.